ChemoMetec A/S (LON:0DZ0)
London · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 944.55M -6.1% |
| Revenue (ttm) | 57.60M +7.3% |
| Net Income | 20.68M +4.7% |
| EPS | 1.19 +4.6% |
| Shares Out | n/a |
| PE Ratio | 45.68 |
| Forward PE | 39.02 |
| Dividend | 0.82 (1.60%) |
| Ex-Dividend Date | Oct 10, 2025 |
| Volume | 2,722 |
| Open | 465.40 |
| Previous Close | 447.38 |
| Day's Range | 464.00 - 480.00 |
| 52-Week Range | 236.00 - 799.25 |
| Beta | 1.38 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 10, 2026 |
About ChemoMetec
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202... [Read more]
Financial Performance
In fiscal year 2025, ChemoMetec's revenue was 495.57 million, an increase of 21.50% compared to the previous year's 407.87 million. Earnings were 186.41 million, an increase of 36.78%.
Financial numbers in DKK Financial StatementsNews
ChemoMetec Appoints Price As CFO, Nikolajsen To Resign
(RTTNews) - ChemoMetec A/S, a biotechnology company, on Saturday announced the appointment on Phillip Massie Price as the new Chief Financial Officer (CFO), effective from August 3, 2026.
ChemoMetec Quarterly report: Q3 2026
ChemoMetec has published its Q3 2026 quarterly earnings report on May 6, 2026.
Chemometec upgraded to Buy from Hold at SEB Equities
SEB Equities upgraded Chemometec (CHHMF) to Buy from Hold with a DKK 400 price target
Chemometec price target lowered to DKK 900 from DKK 970 at Berenberg
Berenberg lowered the firm’s price target on Chemometec (CHHMF) to DKK 900 from DKK 970 and keeps a Buy rating on the shares.
ChemoMetec Quarterly report: Q2 2026
ChemoMetec has published its Q2 2026 quarterly earnings report on February 4, 2026.
ChemoMetec Transcript: Q1 25/26
Revenue grew 8% year-over-year with strong XM platform adoption and improved margins. Upgraded guidance reflects broad customer interest, with larger XM orders expected by fiscal year-end. Strategic focus is on software and automation, supporting long-term profitability.
ChemoMetec Earnings release: Q1 2026
ChemoMetec released its Q1 2026 earnings on November 7, 2025, summarizing the period's financial results.
ChemoMetec Transcript: Q4 24/25
Revenue, EBITDA, and cash flow increased year-over-year, with strong growth across all segments and a high gross margin. Guidance anticipates 10–14% sales growth, margin improvement, and major investments in automation and software, while macro and currency risks remain.
ChemoMetec Annual report: Q4 2025
ChemoMetec has published its Q4 2025 annual report on September 12, 2025.